watermelon101

@avidresearch Same as $NKTR. sigh

$CRVS terrible price action.

$CORT I guess people finally realize it is very under-valued. should be at least $60/s. $NKTR I do not know what is going on. My new add at below $100 is now way underwater. Maybe @A_May_MD should do another long post educating people how low the valuation is🤑. Ha!

Just ignore the price noise in $QURE and patiently wait for more data. I know MM and VP not liking the data as it is not clear cut but can not understand the strong animosity towards it by them. Nobody knows who is going to replace MM but I do not care. Data speaks eventually.

$CYTK good results. Great science and trial execution. It should trade above $90 but with the Blum discount maybe $80ish. Offering may be coming also.

Bought $CELC this morning around $140. TAM seems very big (>4B). fair value should be around $200 IMHO. Waiting for the details in ASCO.

I guess the silver lining about this $ERAS data dump fiasco is now they can claim their drug is truly different than darax ( grade 5 pneumonitis !) despite 99% structure similarity. Ha ! sorry $ERAS fans.

The $RVMD $ERAS patent story is very interesting. not a lawyer but does understanding chemistry . It looks like $ERAS ERAS-0015 molecule is just taking the daraxonrasib structure and did absolutely minimum change. Pretty disgraceful IMHO

Got some more $NKTR below $100 this morning. A picture is worth a thousand words. The hair regrowth pictures in their morning presentation is amazing and $NKTR has the potential to become a biotech meme stock. Secondary offering is coming, probably tonight though IMHO

The price tag of $SLNO buyout is a little bit disappointing to me, only assuming a peak sale of around $1B. I guess Scorpions' relentless attack really hurts the sale. $NBIX gets a great deal IMHO

@EpochSwing @plainyogurt21 pretty similar OS delta with relacorilant in PROC. interesting. $CORT

@plainyogurt21 I get your point but object to calling this efficacy marginal when nothing else improves OS in PROC. The efficacy is so meaningful that pts would rather get treat to the point of cataract surgery than discontinue.

All for 4 months OS..... This is a blockbuster drug (maybe this year $1B+) and we have 1/3 needing cataract surgery, nearly everyone with eye issues. On paper, this is a failure of healthcare right? 25k per month for a p much marginal drug? and people still take. Anyhoo: $ZNTL < cash, has a (albeit small) shot at working in a CCNE+ population larger than Elahere's target market. $APRE with same MoA, $ACRV. (Both likely to fail companies)

Have to give FDA credit when credit is due $CORT. Now let 's hope it can give $QURE a fair shot. Not approval but a serious review.

$CORT Relacorilant approved for PROC?! That is shocking! the PDUFA is in July.

I am surprised that $TERN gets buyout at this stage. Maybe $MRK thinks it is worth a gamble at a good price. The data is great but still too early to conclude it is BIC. IMHO Congratulations longs though.

Continue to buy $SLNO here until reaching my 5% size limit. Unless there is another pt death case on the horizonI can not image the valuation make sense here at low 30s.

Looks like $QURE can finally get a FDA review now. I hope there is an Adcom so we can discuss the data thoroughtly. Happy for HD patients too.

@Sanctuary_Bio Any treatment effect seen within one year is more likely placebo effect than anything. $QURE AMT 130's placebo effect is masked by the temp. neuron damage sustained during the surgical procedure IMHO. Hope this Skyhawk data hold LT for HD patients' sake though.

it's pretty crazy that a day after I posted this, Skyhawk posted some pretty interesting data. n=17, pooled. Looks way better than what $QURE showed at that point prnewswire.com/apac/news-rele…

@AlpBugraBasat $QURE only asking for the chance to review the data NOT approval. Back then I am against approval of eteplirsen after looking at the data and Adcom expert vote. I am fine if after review and preferably Adcom vote the judgement is negative but not chance to be reviewed? come on

$QURE fanfare reminds me of the $SRPT setup in late summer 2016, though the FDA tone seems quite different this time. In the case of $SRPT the skeptics ultimately proved right, something worth keeping in mind with $QURE.

@adamfeuerstein The hubris and arrogance this FDA official shows is of the charts. Lack of compassion is even more shocking. Looks like now he is blocking review for the sake of "blocking" without any sound scientific or regulatory justifications. Shame on him. $QURE

Some context for the UniQure $QURE post below: Earlier today, the FDA held a media call with the same "senior FDA official" who spoke to me (and other reporters) individually earlier in the week. The call was set up obstensibly so that this senior FDA official could rail against UniQure without going on the record. He did exactly this for 30 minutes, repeating the same criticisms, claiming Uniqure's Huntington’s therapy is a failure, the sham surgery would be blinded even if just small "nicks" in the skin were made in a 30-minute procedure, dismissing the idea of formally reviewing the therapy, disregarding outside scientific experts, and then accusing the media of not adequately covering what the FDA (and this official) have been doing. Reporters from Bloomberg, STAT, NY Times, WSJ, Politico and other media organizations were on the call.

The $QURE story is over, at least for now. price is down more than I expected but that is OK. Plan is to hold LT. damage is small as my position is not big. There are other HD trials going on but IMHO the chances for them to work is close to none. SAD day for HD pts for sure.

@Liv4theBeat Agreed. very unprofessional.

@jianguangchen It was really such bad form for him to blab about official FDA business that hasn’t gone public, on CNBC of all places

As for Makary's comments "that has morbidity associated with it." I thought $QURE safety is clean. No pt died from the surgery or complications associated with the surgery. So this is strange IMHO